Strategies for prevention of scars: what can we learn from fetal skin?
Open Access
- 6 October 2010
- journal article
- review article
- Published by Wiley in International Journal of Dermatology
- Vol. 50 (1) , 85-93
Abstract
Fetal wound healing occurs rapidly and without scar formation early in gestation. Studying the mechanisms of scarless repair can lead to novel scar‐preventive approaches. In fetal wounds, collagen is deposited early and is fine and reticular with less cross‐linking. Several important differences of fetal vs. postgestational wound‐healing response have been determined, such as the presence of less inflammation, higher hyaluronic acid concentration and a greater ratio of collagen type III to type I. Compared with typical wounds, there are also altered ratios of signaling molecules, such as higher ratios of transforming growth factor (TGF)‐β3 to TGF‐β1 and ‐β2, and matrix metalloproteinases to tissue inhibitors of metalloproteinases. Furthermore, fetal fibroblasts do not exhibit TGF‐β1‐induced collagen production compared with their mature counterparts. Patterning genes (homeobox genes) involved in organogenesis are more active in the fetal period and are believed to be the “first domino” in the fetal cutaneous wound repair regulatory cascade. The recommended scar‐preventive agents, such as Scarguard MD®, silicone gel and sheet, Seprafilm® Bioresorbable Membrane, topical hyaluronan, onion extract, oral tamoxifen and 585‐nm pulsed dye laser are reviewed in this study. Despite the lack of supporting evidence, there is a widespread false presumption that the acceleration of healing with the widely assumed scar‐preventive commercial agents is associated with decreased scar formation. Humans are erroneously inclined to make a negative correlation between the healing rate and the degree of scar formation, while such a correlation does not exist in reality. Despite the importance of scar prevention, no FDA‐approved therapy for this purpose is available in the 21st century, which reflects the important challenges, such as the presence of redundant pathways, that these approaches are facing.Keywords
This publication has 55 references indexed in Scilit:
- Expression of Integrin αvβ6 and TGF-β in Scarless vs Scar-forming Wound HealingJournal of Histochemistry & Cytochemistry, 2009
- Hypertrophic Scars and Keloids—A Review of Their Pathophysiology, Risk Factors, and Therapeutic ManagementDermatologic Surgery, 2009
- Blood-derived small Dot cells reduce scar in wound healingExperimental Cell Research, 2008
- Molecular Basis for the Regenerative Properties of a Secretion of the Mollusk Cryptomphalus aspersaSkin Pharmacology and Physiology, 2007
- Cutaneous tissue angiotensin–converting enzyme may participate in pathologic scar formation in human skinJournal of the American Academy of Dermatology, 2006
- Double-Blind, Randomized, Placebo-Controlled, Prospective Study Evaluating the Tolerability and Effectiveness of Imiquimod Applied to Postsurgical Excisions on Scar CosmesisDermatologic Surgery, 2005
- Botulinum Toxin to Minimize Facial ScarringFacial Plastic Surgery, 2002
- Physiologically low oxygen concentrations determined in fetal skin regulate hypoxia‐inducible factor 1 and transforming growth factor β3The FASEB Journal, 2002
- The Effects of Topical Vitamin E on the Cosmetic Appearance of ScarsDermatologic Surgery, 1999
- Glucosamine for wound healingMedical Hypotheses, 1996